Showing results (231-240 of 247) with videos related to
Sort By:
Pageof 25
Bioorganic & Medicinal Chemistry Letters|October 31, 2012
Structure-based discovery of C-2 substituted imidazo-pyrrolopyridine JAK1 inhibitors with improved selectivity over JAK2Sharada Labadie, Peter S Dragovich, Kathy Barrett, et al.Microbial Cell Factories|July 25, 2024
Producing recombinant proteins in Vibrio natriegensMatthew Smith, José Sánchez Hernández, Simon Messing, et al.Bioorganic & Medicinal Chemistry Letters|May 7, 2013
Novel triazolo-pyrrolopyridines as inhibitors of Janus kinase 1Christopher A Hurley, Wade S Blair, Richard J Bull, et al.Bioorganic & Medicinal Chemistry Letters|October 22, 2013
Structure-based design and synthesis of potent benzothiazole inhibitors of interleukin-2 inducible T cell kinase (ITK)Colin H MacKinnon, Kevin Lau, Jason D Burch, et al.Nature Communications|September 8, 2023
Pre-clinical validation of a pan-cancer CAR-T cell immunotherapy targeting nfP2X7Veronika Bandara, Jade Foeng, Batjargal Gundsambuu, et al.Journal of Medicinal Chemistry|December 23, 2016
Structure-Based Design of Tricyclic NF-κB Inducing Kinase (NIK) Inhibitors That Have High Selectivity over Phosphoinositide-3-kinase (PI3K)Georgette M Castanedo, Nicole Blaquiere, Maureen Beresini, et al.Bioorganic & Medicinal Chemistry Letters|April 15, 2019
Discovery of a class of highly potent Janus Kinase 1/2 (JAK1/2) inhibitors demonstrating effective cell-based blockade of IL-13 signalingMark Zak, Emily J Hanan, Patrick Lupardus, et al.European Journal of Medicinal Chemistry|July 23, 2013
Lead identification of novel and selective TYK2 inhibitorsJun Liang, Vickie Tsui, Anne Van Abbema, et al.Bioorganic & Medicinal Chemistry Letters|August 24, 2017
Identification of an imidazopyridine scaffold to generate potent and selective TYK2 inhibitors that demonstrate activity in an in vivo psoriasis modelJun Liang, Anne Van Abbema, Mercedesz Balazs, et al.Journal of Medicinal Chemistry|May 18, 2012
Identification of imidazo-pyrrolopyridines as novel and potent JAK1 inhibitorsJanusz J Kulagowski, Wade Blair, Richard J Bull, et al.Pageof 25